HER2低表达胃腺癌临床病理特征  

Clinicopathological characteristics of HER2 low expression gastric adenocarcinoma

作　　者：牟依琳 林东亮[2] 赵树超[2] 史海磊 何慧 张海燕[3] 邢晓明[2] Mu Yilin;Lin Dongliang;Zhao Shuchao;Shi Hailei;He Hui;Zhang Haiyan;Xing Xiaoming(School of Basic Medicine,Qingdao University,Qingdao 266071,China;Department of Pathology,Affiliated Hospital of Qingdao University,Qingdao 266000,China;Department of Pathology,Linyi People’s Hospital,Shandong Province,Linyi 276000,China)

机构地区：[1]青岛大学基础医学院,青岛266071 [2]青岛大学附属医院病理科,青岛266000 [3]山东省临沂市人民医院病理科,临沂276000

出　　处：《临床与实验病理学杂志》2025年第3期334-339,共6页Chinese Journal of Clinical and Experimental Pathology

摘　　要：目的探讨胃癌患者中HER2低表达的比例及与临床病理特征的关系。方法收集3779例胃腺癌根治患者的临床资料,采用免疫组化联合FISH法对其进行HER2表达分类,分析HER2低表达胃腺癌患者的临床病理特征与预后。结果3779例胃腺癌中HER2低表达1251例(33.10%)。HER2低表达与0表达相比,其患者倾向于高龄男性、分化相对较高的Lauren肠型腺癌且癌组织不易侵犯神经;Ki67增殖指数、临床分期也更高。同时与HER2过表达相比,HER2低表达患者倾向于低龄女性、分化相对较差的Lauren弥漫型腺癌且癌组织更易侵犯神经,其Ki67增殖指数、临床分期更低。HER2低表达胃腺癌患者与0表达、过表达患者的预后无明显差异。结论胃腺癌患者中HER2低表达占比较大,HER2相关抗体偶联药物可能对HER2低表达患者提供有效的治疗机会。Purpose To explore the relationship between the proportion of HER2 low expression and clinicopathological characteristics of gastric adenocarcinoma patients.Methods Clinical data from 3779 gastric adenocarcinoma patients who underwent radical resection were collected.HER2 expression was categorized using immunohistochemistry combined with FISH,and the clinicopathological characteristics and prognosis of HER2 low expression gastric adenocarcinoma patients were analyzed.Results Among the 3779 gastric adenocarcinoma cases,1251 cases(33.10%)showed HER2 low expression.Compared with HER2 negative expression,HER2 low expression patients were more likely to be older males,present with well-differentiated Lauren’s intestinal-type adenocarcinoma,and have less nerve invasion.Furthermore,compared to HER2 negative expression,they showed higher Ki67 proliferation index and more advanced clinical stage.Meanwhile,compared with patients with HER2 over expression,those with low HER2 expression were more likely to be younger females,present with well-differentiated Lauren’s diffuse-type adenocarcinoma,and have more nerve invasion.Furthermore,compared to HER2 over expression,they showed lower Ki67 proliferation index and more advanced clinical stage.There was no significant difference in prognosis between HER2 low expression,HER2 negative,and HER2 over expression groups.Conclusion HER2 low expression have a relatively large proportion in gastric adenocarcinoma patients,and HER2-targeted antibody-drug conjugates may provide an effective treatment option for these patients with HER2 low expression.

关 键 词：胃肿瘤 腺癌 HER2低表达 临床病理特征 预后 

分 类 号：R735.2[医药卫生—肿瘤]